TOULOUSE, France– (BUSINESS WIRE) — As part of its pre-marketing studies, Vexim, a high-technology company specialized in medical instrumentation, and in the minimally-invasive anatomical treatment of vertebral compression fractures, announced positive clinical trial results and achievement of its recruitment objective of 120 patients by June 15th.
Over a year ago, Vexim initiated two clinical studies, including an international trial with 8 centers in Germany, France, Spain, Portugal and Turkey. This clinical work (featuring 120 patients and a 12 month follow-up period) has helped to optimise the SpineJack® implant with a view to market launch in 2009 within the next few weeks.
By successfully completing these studies, Vexim has proved the efficacy of its SpineJack® implant for the controlled, morphological restoration of vertebral compression fractures. Following implantation of the SpineJack®, all patients experienced rapid pain relief and correction of post-trauma deformation (visually assessed by conventional radiography, computed tomography scanning and a very accurate three-dimensional mapping tool developed in the LBM lab at the Paris ENSAM engineering school).